搜索筛选:
搜索耗时4.2360秒,为你在为你在102,285,761篇论文里面共找到 4 篇相符的论文内容
发布年度:
The Efficacy And Adverse Reactions Of Different Doses Of Isonlazid Treatment Intuberculous Meningiti
[会议论文] 作者：Luolan Wei,Wenxiang Huang,Xiaojuan Xin,Zhen Yin,
来源：第四届国际人体微生态大会、第十三届中华预防医学会微生态学学术会议、第五届中国医师协会感染科医师大会暨传染病诊治高峰论坛、 年份：2013
...
The Efficacy And Adverse Reactions Of Different Doses Of Isonlazid Treatment Intuberculous Meningiti
[会议论文] 作者：Luolan Wei,Wenxiang Huang,Xiaojuan Xin,Zhen Yin,
来源：第四届国际人体微生态大会、第十三届中华预防医学会微生态学学术会议、第五届中国医师协会感染科医师大会暨传染病诊治高峰论坛、 年份：2013
...
A Multicenter,Randomized Controlled Clinical Study on Ceftriaxone/Sulbactam and Cefoperazone/Sulbact
[会议论文] 作者：Xiaojuan Xin,Yunhua Liao,Yijiang Huang,Yunkui Zhu,Chunsheng Xi,Weili Zhang,Ling Zhong,Bei Jia,Wenxiang,
来源：中国药理学会第十一届全国化疗药理学术研讨会 年份：2012
Background Cettriaxone/sulbactam(4∶1)is a novel β-lactam/β-lactamase-inhibitor combination injection.A clinical study was designed to evaluate its efficacy and safety in the treatment of respiratory a...
A Multicenter,Randomized Controlled Clinical Study on Ceftriaxone/Sulbactam and Cefoperazone/Sulbact
[会议论文] 作者：Xiaojuan Xin,Yunhua Liao,Yijiang Huang,Yunkui Zhu,Chunsheng Xi,Weili Zhang,Ling Zhong,Bei Jia,Wenxiang,
来源：第四届国际人体微生态大会、第十三届中华预防医学会微生态学学术会议、第五届中国医师协会感染科医师大会暨传染病诊治高峰论坛、 年份：2013
Background Ceftriaxone/sulbactam (4:1) is a novel β-lactam/β-lactamase-inhibitor combination injection.A clinical study was designed to evaluate its efficacy and safety in the treatment of respiratory...
相关搜索：
